A novel predictive model of outcome in acute myeloid leukemia without favorable karyotype based on treatment strategy, karyotype and FLT3-ITD mutational status

Am J Hematol. 2018 Dec;93(12):E401-E404. doi: 10.1002/ajh.25290. Epub 2018 Oct 17.

Authors

Kebede H Begna¹, Walid Ali¹, Naseema Gangat¹, Michelle A Elliott¹, Aref Al-Kali¹, Mark R Litzow¹, C Christopher Hook¹, Alexandra P Wolanskyj¹, William J Hogan¹, Mrinal M Patnaik¹, Animesh Pardanani¹, Darci L Zblewski¹, Dong Chen², Rong He², David Viswanatha², Curtis A Hanson², Rhett P Ketterling³, Ayalew Tefferi¹

Affiliations

¹ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.
² Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota.
³ Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota.

PMID: 30230610
DOI: 10.1002/ajh.25290

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Female
Humans
Karyotype*
Leukemia, Myeloid, Acute / diagnosis*
Leukemia, Myeloid, Acute / genetics
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / therapy*
Male
Middle Aged
Mutation
Prognosis
Remission Induction
Stem Cell Transplantation
Survival Analysis
Transplantation, Homologous
Treatment Outcome
Young Adult
fms-Like Tyrosine Kinase 3 / genetics*

Substances

FLT3 protein, human
fms-Like Tyrosine Kinase 3